{
    "2018-11-08": [
        [
            {
                "time": "",
                "original_text": "华东医药：完成现金要约收购英国Sinclair全部股份",
                "features": {
                    "keywords": [
                        "华东医药",
                        "现金要约收购",
                        "英国",
                        "Sinclair"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "北上资金年内“壕买”A股逾2500亿 10只强势股成主角",
                "features": {
                    "keywords": [
                        "北上资金",
                        "A股",
                        "2500亿",
                        "强势股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业:三季报业绩稳健,关注低估值及龙头绩优股",
                "features": {
                    "keywords": [
                        "医药生物",
                        "三季报",
                        "业绩稳健",
                        "低估值",
                        "龙头绩优股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2018年11月投资策略报告:一阳来复,否极泰来",
                "features": {
                    "keywords": [
                        "医药行业",
                        "2018年11月",
                        "投资策略",
                        "一阳来复",
                        "否极泰来"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业专题报告:收入整体稳健,Q3扣非净利润增速放缓,内部分化持续",
                "features": {
                    "keywords": [
                        "医药生物",
                        "收入稳健",
                        "Q3",
                        "扣非净利润",
                        "增速放缓",
                        "内部分化"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}